PET Agents Beyond Oncology
Description
For decades, PET imaging was nearly synonymous with FDG. With improvements in PET technology, investment resulting from the emergence of theranostics, and improvements in reimbursement, the landscape of PET has shifted dramatically in recent years. Brain pathology research relies heavily on PET imaging, and as a result there are currently three FDA approved agents for amyloid-beta imaging, one for tau imaging, and one for Parkinson's imaging. There is also a newly FDA approved agent for cardiac rest/stress evaluation in addition to those agents that have been used for years. This session will familiarize the audience with these non-oncologic agents as well as select other agents and isotopes that are of interest for future clinical use.